Drug Trial Radar · NCT07895394
Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Oct 27, 2026
Primary completion
Oct 2027
Study completion Oct 2028
Sponsor
- Lead sponsor
- Seoul National University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the immunogenicity and safety of respiratory syncytial virus (RSV) vaccination between lung transplant recipients and immunocompetent adults and to provide evidence to guide RSV vaccination in lung transplant recipients.
Conditions
- Vaccination
- Respiratory Syncytial Virus (RSV)
- Lung Transplant Recipient
Interventions
RSVPreF3 vaccinationBiological
One dose of RSVPreF3 (Arexvy®) vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Humoral immune response (neutralizing antibody)Time frame: 1 month after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, Jongno-Gu, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.